Calquence shows long-term efficacy and tolerability in MCL
Patients with relapsed or refractory mantle cell lymphoma (MCL) treated with AstraZeneca’s Calquence remained progression free for a median of 22 months
Read More
Tag: NHL
Poteligeo approved in Europe for Mycosis Fungoides, Sézary Syndrome
Kyowa Hakko Kirin (Kyowa Kirin) has received marketing authorisation Europe for use of Poteligeo to treat Mycosis Fungoides and Sézary Syndrome.
Read More
CTI, Servier’s Pixuvri fails in post-marketing trial
A late-stage trial of Servier and CTI BioPharma’s Pixuvri in combination with Roche’s MabThera has failed to hit targets in B-cell non-Hodgkin lymphoma, putting its conditional approval in Europe in jeopardy.
Read More
Genmab/Novatis’ Arzerra fails to hit NHL targets
Adding Arzerra to treatment with Treanda has failed to significantly extend progression-free survival in patients with indolent B cell non-Hodgkin’s lymphoma.
Read More
Bayer’s rare cancer drug Aliqopa bags speedy approval
US regulators have issued an accelerated approval for Bayer’s relapsed follicular lymphoma therapy Aliqopa.
Read More
Gilead buys into CAR-T with $11.9bn deal for Kite
Gilead Sciences is buying Kite Pharma in a deal worth $11.9 billion, securing itself access to the latter’s experimental CAR-T therapy axicabtagene ciloleucel and wider cancer pipeline.
Read More
Kite first to submit CAR-T therapy in Europe
Kite Pharma has submitted the first CAR-T cell therapy in Europe, seeking permission to market its axicabtagene ciloleucel (axi-cel) to treat patients with three subtypes of aggressive non-Hodgkin lymphoma (NHL).
Read More
Mundipharma to launch Mabthera biosimilar in EU markets
Mundipharma is gearing up to launch biosimilar Truxima in seven European markets for the treatment of certain cancers and inflammatory conditions, after Celltrion bagged a regulatory approval for the drug.
Read More
NICE turns down Janssen’s Imbruvica for rare blood cancer
Cost regulators for the NHS in England and Wales have turned down Janssen’s Imbruvica for treating some people with Waldenstrom’s macroglobulinaemia (WM) – a rare type of slow growing non-Hodgkin’s lymphoma.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
